News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nuclea Biotechnologies Release: New Data Points To Prognostic & Predictive Value Of Nuclea’s Serum HER-2/neu



6/17/2014 11:34:31 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PITTSFIELD, Mass.--(BUSINESS WIRE)--At the 50th meeting of the American Society for Clinical Oncology (ASCO), Nuclea Biotechnologies presented the conclusion of a recent study which reinforced the findings of previous clinical studies pointing to the prognostic and predictive value of serum HER-2/neu testing for patients with metastatic breast cancer (MBC).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES